安慰剂免疫相关不良事件(irAEs):癌症免疫治疗试验中被忽视的现象
该研究检索公共数据库,纳入免疫检查点抑制剂(ICI)对比安慰剂的随机对照试验(RCT),采用随机效应模型进行Meta分析。47项RCT共30,119例患者中,安慰剂组任何级别和3至5级irAEs的合并比例分别为22.85%(17.33%-29.50%)和3.40%(2.35%-4.63%)。安慰剂联合非免疫治疗对照组的假性irAE比值显著高于单纯安慰剂对照组。
要点
- 47项RCT共30,119例患者,安慰剂组任何级别irAEs合并比例为22.85%(17.33%-29.50%)。
- 安慰剂组3至5级irAEs合并比例为3.40%(2.35%-4.63%)。
- 安慰剂联合非免疫治疗对照组的假性irAE比值显著高于单纯安慰剂组。
核心结论
- 对ICI随机对照试验中安慰剂治疗参与者的分析记录了安慰剂irAEs的常见发生。
- 这些发现对于解读irAE特征、避免不恰当的治疗干预具有重要意义。
研究设计与样本
- 研究检索公共数据库,纳入ICI对比安慰剂治疗恶性肿瘤患者的随机对照试验(RCT)。
- 提取研究特征和irAEs发生情况,采用随机效应模型进行Meta分析。
- 共分析47项RCT,30,119例患者。
主要发现
- 安慰剂组任何级别irAEs的合并比例为22.85%(17.33%-29.50%),3至5级irAEs的合并比例为3.40%(2.35%-4.63%)。
- 安慰剂组严重irAEs的合并比例为0.67%(0.03%-1.91%)。
- 因安慰剂irAEs停药和死亡的患者比例分别为0.69%(<0.01%-1.30%)和0.12%(<0.01%-0.40%)。
- 任何级别和3至5级irAEs的假性irAE比值分别为0.49和0.28。
- 安慰剂联合非免疫治疗对照组的假性irAE比值显著高于单纯安慰剂对照组:任何级别为0.57 vs 0.32(P < 0.001),3至5级为0.36 vs 0.12(P = 0.009)。
关键数值与推荐
- 任何级别irAEs的假性irAE比值为0.49。
- 3至5级irAEs的假性irAE比值为0.28。
- 安慰剂联合非免疫治疗对照组任何级别假性irAE比值为0.57,单纯安慰剂对照组为0.32(P < 0.001)。
- 安慰剂联合非免疫治疗对照组3至5级假性irAE比值为0.36,单纯安慰剂对照组为0.12(P = 0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to investigate the underexplored prevalence of placebo-reported immune-related adverse events (irAEs) in immune checkpoint inhibitor (ICI) trials. METHODS: We searched public databases for randomized clinical trials (RCTs) involving ICI versus placebo treatments in patients with malignancies. Study characteristics and irAEs occurrences were extracted for meta-analyses using a random-effects model. MAIN OUTCOMES: Proportions of patients reported to experience any grade and grade 3 to 5 placebo irAEs; the risk ratio (RR) of reporting 'false' irAEs in the experiment arm (defined as 'false-irAE ratio', calculated by dividing the proportion of patients documented with irAEs in the placebo arm by that in the experimental arm). RESULTS: 47 RCTs with 30,119 patients were analyzed. The pooled proportion of patients reported to experience any grade and grade 3 to 5 irAEs among placebo participants was 22.85 % (17.33 %-29.50 %) and 3.40 % (2.35 %-4.63 %), respectively. The pooled proportion of placebo-treated patients who experienced serious irAEs was 0.67 % (0.03 %-1.91 %). Treatment discontinuation and death due to placebo irAEs occurred in 0.69 % (<0.01 %-1.30 %) and 0.12 % (<0.01 %-0.40 %) of patients, respectively. The false-irAE ratio for any grade and grade 3 to 5 irAEs were 0.49 and 0.28. The false-irAE ratio was significantly higher in RCTs with control arms of placebo plus non-immunotherapy than in those with placebo alone (any grade: 0.57 vs. 0.32, P < 0.001; grade 3 to 5: 0.36 vs. 0.12, P = 0.009). CONCLUSION: Our analyses of placebo-treated participants in ICI RCTs document the common occurrence of placebo irAEs. These findings are important for interpreting irAE profiles, avoiding inappropriate therapeutic interventions.
引用
- Zhou Y, Yu H, Chen C, et al. Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials. Eur J Cancer. 2024. PMID: 38981314. doi:10.1016/j.ejca.2024.114203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。